Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
2023 · Nature · 1,154 citations
https://doi.org/10.1038/s41586-023-06063-y
O
Olca Baştürk
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
426
Papers
20.0K
Citations
66
h-index
171
i10-index
Olca Baştürk is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cholangiocarcinoma and Gallbladder Cancer Studies & Neuroendocrine Tumor Research Advances. The author has an h-index of 66, co-authored 363 publications.
ORCID: 0000-0003-2747-1366Papers by this author
worksOverview of the 2022 WHO Classification of Neuroendocrine Neoplasms
2022 · Endocrine Pathology · 866 citations
https://doi.org/10.1007/s12022-022-09708-2
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies
2014 · Modern Pathology · 229 citations
https://doi.org/10.1038/modpathol.2014.156
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
2024 · Nature Medicine · 205 citations
https://doi.org/10.1038/s41591-023-02760-3
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
2025 · Nature · 187 citations
https://doi.org/10.1038/s41586-024-08508-4
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
2025 · Nature Medicine · 60 citations
https://doi.org/10.1038/s41591-024-03362-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat